Pubblicazioni

Single-nucleotide FcÎ³ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma

2021 - BLOOD ADVANCES

Strefford, Jonathan C; Nowicka, Malgorzata; Hargreaves, Chantal E; Burton, Cathy; Davies, Andrew; Ganderton, Rosalind; Hiddemann, Wolfgang; Iriyama, Chisako; Klapper, Wolfram; Latham, Kate V; Martelli, Maurizio; Mir, Farheen; Parker, Helen; Potter, Kathleen N; Rose-Zerilli, Matthew J J; Sehn, Laurie H; TrnÄnÃ½, Marek; Vitolo, Umberto; Bolen, Christopher R; Klein, Christian; Knapp, Andrea; Oestergaard, Mikkel Z; Cragg, Mark S

Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment

2021 - BLOOD ADVANCES

Nowicka, Malgorzata; Hilton, Laura K; Ashton-Key, Margaret; Hargreaves, Chantal E; Lee, Chern; Foxall, Russell; Carter, Matthew J; Beers, Stephen A; Potter, Kathleen N; Bolen, Christopher R; Klein, Christian; Knapp, Andrea; Mir, Farheen; Rose-Zerilli, Matthew; Burton, Cathy; Klapper, Wolfram; Scott, David W; Sehn, Laurie H; Vitolo, Umberto; Martelli, Maurizio; Trneny, Marek; Rushton, Christopher K; Slack, Graham W; Farinha, Pedro; Strefford, Jonathan C; Oestergaard, Mikkel Z; Morin, Ryan D; Cragg, Mark S